Biology-Driven Technologies to Assess Cancer Lecture Part of Alvine Engineering Series at UNH
The University of New Haven (UNH) Tagliatela College of Engineering will host a free public lecture, "Systems Biology-Driven Technologies to Assess Cancer Heterogeneity," by Rong Fan, professor of chemistry at the University of California at Berkeley. Fan's lecture is part of the UNH Spring 2011 Alvine Engineering Professional Effectiveness and Enrichment Program.
According to Fan, the singular term "cancer" deceivingly encompasses a large number of heterogeneous disease states, requiring systems approaches for patient stratification and personalized treatment. He will present the development of a nanoliter-fluidic chip that rapidly separates plasma from blood cells and simultaneously measures a panel of plasma proteins from a finger prick of whole blood. He also will discuss an integrated nano-liter microchamber array for high-content profiling of protein secretome from individual cells, enabling rapid delineation of functional heterogeneity at the single cell level. These novel nanobiotechnology platforms hold potential for inexpensive, non-invasive and informative clinical diagnosis particularly for point-of-care treatment. In addition, he will provide an overview of related nanobiotechnologies for cancer diagnosis and therapeutics, and note how these emerging technologies will transform the medicines used for the current passive mode of cancer treatment to a preventative, predictive and personalized mode of treatment in the future.
Wednesday, March 9, 12:15-1:30 p.m.
The Schumann Auditorium in the Tagliatela College of Engineering, Room B120, Buckman Hall, UNH Main Campus, 300 Boston Post Road, West Haven, Conn.
Fan received his doctorate in chemistry from the University of California at Berkeley, where his research was focused on single nanotube nanofluidics. After completing his doctorate, he joined the Nanosystems Biology Cancer Center (NSBCC) at the California Institute of Technology, where he developed an integrated bar-code chip that allows highly multiplexed plasma protein measurement from a finger prick of blood. His current research focuses on systems biology-driven nanotechnologies for differential diagnosis and stratification of cancer and autoimmune disease in order to enable individualized therapy. He was selected for the outstanding trainee researcher in the National Cancer Institute Alliance for Nanotechnology in Cancer. He is the recipient of numerous awards including the National Institutes of Health Howard Temin Pathway to Independence Award and the Bill & Melinda Gates Foundation Grand Challenges Explorations Award.
For more information contact Ismail Orabi at 203-932-7144 or email@example.com.